PCSK9 Gene Editing Therapy Shows Deep LDL Cholesterol

What Did VERVE-102 Show In The Heart-2 Trial?

VERVE-102 is an investigational in vivo base-editing medicine designed to turn off the PCSK9 gene in liver cells. In the ongoing Heart-2 Phase 1b study, Lilly reported that 35 adults with heterozygous familial hypercholesterolemia or premature coronary artery disease received a single intravenous infusion across ascending dose groups.

The reported response was dose dependent: PCSK9 protein fell by up to 88%, while LDL-C fell by up to 62% at the highest dose. Lilly said reductions were sustained during follow-up of up to 18 months in some participants, and no treatment-related serious adverse events or dose-limiting toxicities were reported in this interim analysis.

How Could PCSK9 Base Editing Lower LDL Cholesterol?

PCSK9 is a well-established cholesterol target. The PCSK9 protein promotes degradation of LDL receptors, which are needed to remove LDL cholesterol from circulation. Existing PCSK9 monoclonal antibodies and small interfering RNA therapies lower LDL-C by blocking or reducing PCSK9 activity, but they require repeated injections.

VERVE-102 takes a different approach. It delivers messenger RNA for an adenine base editor and a guide RNA inside a liver-targeted lipid nanoparticle, with the goal of making a durable DNA edit in the PCSK9 gene. That strategy is intended to mimic naturally occurring PCSK9 loss-of-function variants, which have been linked to lower lifetime LDL-C and lower coronary heart disease risk.

What Should Patients Know Before Gene Editing Reaches Clinics?

The early results are scientifically important, but they do not mean gene editing is ready to replace statins, ezetimibe, PCSK9 inhibitors, or lifestyle-based prevention. Phase 1 studies are primarily designed to assess safety, tolerability, and biological effect; they are not large enough to prove reductions in cardiovascular events.

Long-term follow-up will be especially important because base editing is intended to be durable. Researchers and regulators will need to monitor liver safety, immune reactions, off-target editing risk, durability of LDL-C lowering, and whether the benefit-risk profile is appropriate for people who already have effective reversible treatment options.